AXON
Price
$780.00
Change
+$20.93 (+2.76%)
Updated
Jun 4, 04:59 PM (EDT)
Capitalization
60.72B
69 days until earnings call
BEAM
Price
$17.14
Change
+$0.26 (+1.54%)
Updated
Jun 4, 04:59 PM (EDT)
Capitalization
1.72B
69 days until earnings call
Interact to see
Advertisement

AXON vs BEAM

Header iconAXON vs BEAM Comparison
Open Charts AXON vs BEAMBanner chart's image
Axon Enterprise
Price$780.00
Change+$20.93 (+2.76%)
Volume$1.86K
Capitalization60.72B
Beam Therapeutics
Price$17.14
Change+$0.26 (+1.54%)
Volume$17.78K
Capitalization1.72B
AXON vs BEAM Comparison Chart
Loading...
AXON
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BEAM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AXON vs. BEAM commentary
Jun 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AXON is a StrongBuy and BEAM is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 05, 2025
Stock price -- (AXON: $759.07 vs. BEAM: $16.88)
Brand notoriety: AXON and BEAM are both not notable
AXON represents the Aerospace & Defense, while BEAM is part of the Biotechnology industry
Current volume relative to the 65-day Moving Average: AXON: 82% vs. BEAM: 63%
Market capitalization -- AXON: $60.72B vs. BEAM: $1.72B
AXON [@Aerospace & Defense] is valued at $60.72B. BEAM’s [@Biotechnology] market capitalization is $1.72B. The market cap for tickers in the [@Aerospace & Defense] industry ranges from $267.54B to $0. The market cap for tickers in the [@Biotechnology] industry ranges from $318.09B to $0. The average market capitalization across the [@Aerospace & Defense] industry is $19.52B. The average market capitalization across the [@Biotechnology] industry is $2.31B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AXON’s FA Score shows that 3 FA rating(s) are green whileBEAM’s FA Score has 1 green FA rating(s).

  • AXON’s FA Score: 3 green, 2 red.
  • BEAM’s FA Score: 1 green, 4 red.
According to our system of comparison, AXON is a better buy in the long-term than BEAM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AXON’s TA Score shows that 2 TA indicator(s) are bullish while BEAM’s TA Score has 3 bullish TA indicator(s).

  • AXON’s TA Score: 2 bullish, 5 bearish.
  • BEAM’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, BEAM is a better buy in the short-term than AXON.

Price Growth

AXON (@Aerospace & Defense) experienced а +1.74% price change this week, while BEAM (@Biotechnology) price change was -0.88% for the same time period.

The average weekly price growth across all stocks in the @Aerospace & Defense industry was +6.01%. For the same industry, the average monthly price growth was +18.08%, and the average quarterly price growth was +32.84%.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.26%. For the same industry, the average monthly price growth was +5.04%, and the average quarterly price growth was -2.58%.

Reported Earning Dates

AXON is expected to report earnings on Aug 12, 2025.

BEAM is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Aerospace & Defense (+6.01% weekly)

Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.

@Biotechnology (+6.26% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AXON($60.7B) has a higher market cap than BEAM($1.73B). AXON YTD gains are higher at: 27.721 vs. BEAM (-31.935). AXON has higher annual earnings (EBITDA): 398M vs. BEAM (-399.03M). AXON has more cash in the bank: 2.37B vs. BEAM (1.22B). BEAM has less debt than AXON: BEAM (158M) vs AXON (2.05B). AXON has higher revenues than BEAM: AXON (2.23B) vs BEAM (63.6M).
AXONBEAMAXON / BEAM
Capitalization60.7B1.73B3,519%
EBITDA398M-399.03M-100%
Gain YTD27.721-31.935-87%
P/E Ratio187.95N/A-
Revenue2.23B63.6M3,500%
Total Cash2.37B1.22B194%
Total Debt2.05B158M1,296%
FUNDAMENTALS RATINGS
AXON: Fundamental Ratings
AXON
OUTLOOK RATING
1..100
24
VALUATION
overvalued / fair valued / undervalued
1..100
99
Overvalued
PROFIT vs RISK RATING
1..100
7
SMR RATING
1..100
54
PRICE GROWTH RATING
1..100
1
P/E GROWTH RATING
1..100
7
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
AXONBEAM
RSI
ODDS (%)
Bearish Trend 2 days ago
56%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
65%
Bullish Trend 2 days ago
82%
Momentum
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
74%
Bearish Trend 2 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
78%
Declines
ODDS (%)
Bearish Trend 14 days ago
67%
Bearish Trend 6 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
64%
Bullish Trend 2 days ago
81%
Aroon
ODDS (%)
Bullish Trend 2 days ago
72%
Bearish Trend 2 days ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
AXON
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BEAM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
WGMVX4.060.05
+1.25%
Wasatch Micro Cap Value Institutional
TWGAX14.05N/A
N/A
American Century International Gr A
FAGOX175.40N/A
N/A
Fidelity Advisor Growth Opps M
EGWAX13.19N/A
N/A
Allspring Discovery Small Cap Gr Gr A
IVOAX18.30N/A
N/A
Macquarie Mid Cap Income Opps A